Mendus has initiated the Phase Ib DIVA trial, marking the first clinical evaluation of vididencel in combination with venetoclax and azacitidine (Ven+Aza) in newly diagnosed acute myeloid leukaemia (AML) patients considered unfit for intensive induction chemotherapy or transplantation. Trial preparations are complete and all regulatory clearances have been obtained, with the study led by Professor Andrew Wei and supported by the Olivia Newton John Cancer Research Institute. DIVA will enrol 24 participants and assess safety, immune activity and measurable residual disease (MRD) reduction. A first safety readout from six patients is expected in H127, followed by initial top-line data from all 24 patients in H227. We view the initiation as another tangible step in Mendus’s broadened AML strategy, extending the clinical utility of vididencel to the increasingly relevant Ven+Aza treatment setting and expanding its potential post-remission application.